{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:09:14Z","timestamp":1745467754283,"version":"3.40.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-025-10331-8","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:47:07Z","timestamp":1738216027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incisional PSMA PET\/CT-positive recurrences in prostate cancer\u2013 is there an implication on clinical care?"],"prefix":"10.1007","volume":"42","author":[{"given":"Giovanni","family":"Mazzucato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Falkenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Ekrutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunhild","family":"von Amsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angela","family":"Cerruto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"10331_CR1","doi-asserted-by":"publisher","unstructured":"P. Cornford et al., \u201cEAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent,\u201d Aug. 01, 2024, Elsevier B.V. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"10331_CR2","doi-asserted-by":"publisher","unstructured":"Maurer T et al (Sep. 2015) Prostate-specific membrane Antigen-radioguided surgery for metastatic lymph nodes in prostate Cancer. Eur Urol 68(3):530\u2013534. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.034","DOI":"10.1016\/j.eururo.2015.04.034"},{"key":"10331_CR3","doi-asserted-by":"publisher","unstructured":"Berrens AC et al State of the art in prostate-specific membrane Antigen\u2013targeted Surgery\u2014A systematic review. Aug 01 2023 Elsevier B V https:\/\/doi.org\/10.1016\/j.euros.2023.05.014","DOI":"10.1016\/j.euros.2023.05.014"},{"key":"10331_CR4","doi-asserted-by":"publisher","unstructured":"van Leeuwen FWB et al Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. Mar 01 2019 Nat Publishing Group. https:\/\/doi.org\/10.1038\/s41585-018-0140-8","DOI":"10.1038\/s41585-018-0140-8"},{"key":"10331_CR5","doi-asserted-by":"publisher","unstructured":"Knipper S et al (May 2024) Biochemical response of <\u20090.1 ng\/ml predicts therapy-free survival of prostate Cancer patients following prostate-specific membrane Antigen\u2013targeted salvage surgery. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.04.019","DOI":"10.1016\/j.euo.2024.04.019"},{"key":"10331_CR6","doi-asserted-by":"publisher","unstructured":"Tamburo M et al (May 2024) Salvage Radiotherapy PSMA PET\/CT-guided in men with PSA recurrence. Anticancer Res 44(5):2205\u20132210. https:\/\/doi.org\/10.21873\/ANTICANRES.17027","DOI":"10.21873\/ANTICANRES.17027"},{"key":"10331_CR7","doi-asserted-by":"publisher","unstructured":"Falkenbach F et al (Dec. 2024) Patient-reported outcome measures and decision regret after prostate-specific membrane Antigen\u2013targeted Radioguided surgery for oligorecurrent prostate Cancer. Eur Urol Open Sci 70:1\u20137. https:\/\/doi.org\/10.1016\/j.euros.2024.09.010","DOI":"10.1016\/j.euros.2024.09.010"},{"key":"10331_CR8","doi-asserted-by":"publisher","unstructured":"Emmett L et al (Dec. 2017) Treatment outcomes from 68Ga-PSMA PET\/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET. J Nucl Med 58(12):1972\u20131976. https:\/\/doi.org\/10.2967\/jnumed.117.196683","DOI":"10.2967\/jnumed.117.196683"},{"key":"10331_CR9","doi-asserted-by":"publisher","unstructured":"Milenkovic U et al (2023) Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy, Eur Urol Oncol, vol. 6, no. 6, pp. 582\u2013589, Dec. https:\/\/doi.org\/10.1016\/j.euo.2023.02.010","DOI":"10.1016\/j.euo.2023.02.010"},{"key":"10331_CR10","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP et al (2022) Long-term outcomes and genetic predictors of response to Metastasis-Directed Therapy Versus Observation in oligometastatic prostate Cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol 40:3377\u20133382. https:\/\/doi.org\/10.1200\/JCO.22","journal-title":"J Clin Oncol"},{"key":"10331_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO","volume":"36","author":"P Ost","year":"2017","unstructured":"Ost P et al (2017) Surveillance or Metastasis-Directed therapy for oligometastatic prostate Cancer recurrence: a prospective, randomized, Multicenter Phase II Trial. J Clin Oncol 36:446\u2013453. https:\/\/doi.org\/10.1200\/JCO","journal-title":"J Clin Oncol"},{"key":"10331_CR12","doi-asserted-by":"publisher","unstructured":"Steuber T et al (2019) Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study, Eur Urol Focus, vol. 5, no. 6, pp. 1007\u20131013, Nov. https:\/\/doi.org\/10.1016\/j.euf.2018.02.015","DOI":"10.1016\/j.euf.2018.02.015"},{"key":"10331_CR13","doi-asserted-by":"publisher","unstructured":"Gillessen S et al (2023) Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-\/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022, in European Urology, Elsevier B.V., Mar. pp. 267\u2013293. https:\/\/doi.org\/10.1016\/j.eururo.2022.11.002","DOI":"10.1016\/j.eururo.2022.11.002"},{"key":"10331_CR14","doi-asserted-by":"publisher","unstructured":"Ramirez PT, Wolf JK, Levenback C (Oct. 2003) Laparoscopic port-site metastases: etiology and prevention. Gynecol Oncol 91(1):179\u2013189. https:\/\/doi.org\/10.1016\/S0090-8258(03)00507-9","DOI":"10.1016\/S0090-8258(03)00507-9"},{"key":"10331_CR15","doi-asserted-by":"publisher","unstructured":"Fukuda H, Saito R (Jan. 2006) A case of Sister Mary Joseph\u2019s nodule from prostatic cancer. J Dermatol 33(1):46\u201351. https:\/\/doi.org\/10.1111\/j.1346-8138.2006.00009.x","DOI":"10.1111\/j.1346-8138.2006.00009.x"},{"key":"10331_CR16","doi-asserted-by":"publisher","unstructured":"Hansen T, Weckesser M, Sch\u00e4fers M, Gunnemann A (Jan. 2017) Ungew\u00f6hnliche Manifestation eines Prostatakarzinoms: sister-Mary-Joseph-Knoten. Urologe 56(1):50\u201353. https:\/\/doi.org\/10.1007\/s00120-016-0130-5","DOI":"10.1007\/s00120-016-0130-5"},{"issue":"3","key":"10331_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijscr.2014.01.010","volume":"5","author":"\u00d6 Acar","year":"2014","unstructured":"Acar \u00d6, Esen T, Bavbek S, Peker \u00d6, Musao\u01e7lu A (2014) Port site and peritoneal metastases after robot-assisted radical prostatectomy. Int J Surg Case Rep 5(3):131\u2013134. https:\/\/doi.org\/10.1016\/j.ijscr.2014.01.010","journal-title":"Int J Surg Case Rep"},{"key":"10331_CR18","doi-asserted-by":"publisher","unstructured":"Bakht MK et al (Feb. 2019) Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer 26(2):131\u2013146. https:\/\/doi.org\/10.1530\/ERC-18-0226","DOI":"10.1530\/ERC-18-0226"},{"key":"10331_CR19","doi-asserted-by":"publisher","unstructured":"Uprimny C et al (Jun. 2017) 68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 44(6):941\u2013949. https:\/\/doi.org\/10.1007\/s00259-017-3631-6","DOI":"10.1007\/s00259-017-3631-6"},{"key":"10331_CR20","doi-asserted-by":"publisher","unstructured":"Fede Spicchiale C, De Leonardis F, Orecchia L, Germani S, Asimakopoulos AD, Miano R (2024) A challenging diagnosis of prostate cancer seeding in the perineal needle-tract after transperineal biopsy: is PET-CT the imaging of choice? Urol Case Rep, vol. 57, Nov. https:\/\/doi.org\/10.1016\/j.eucr.2024.102852","DOI":"10.1016\/j.eucr.2024.102852"},{"key":"10331_CR21","doi-asserted-by":"publisher","unstructured":"DiLizia EM, Ahdoot M, Daneshvar M, Gomella PT, Yerram NK, Pinto PA (Jan. 2021) Metastasectomy for rectal wall seeding of prostate adenocarcinoma after transrectal prostate biopsy. Urol Case Rep 34. https:\/\/doi.org\/10.1016\/j.eucr.2020.101445","DOI":"10.1016\/j.eucr.2020.101445"},{"key":"10331_CR22","doi-asserted-by":"publisher","unstructured":"D\u00fcwel C et al (Aug. 2016) Rektummukosametastase Beim Prostatakarzinomrezidiv: 68Ga-PSMA-PET\/CT erm\u00f6glicht eine gezielte Salvagestrahlentherapie. Urologe 55(8):1086\u20131088. https:\/\/doi.org\/10.1007\/s00120-016-0169-3","DOI":"10.1007\/s00120-016-0169-3"},{"key":"10331_CR23","doi-asserted-by":"publisher","unstructured":"Weng CC et al (2019) Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis, Oncogene, vol. 38, no. 12, pp. 2005\u20132019, Mar. https:\/\/doi.org\/10.1038\/s41388-018-0575-7","DOI":"10.1038\/s41388-018-0575-7"},{"key":"10331_CR24","doi-asserted-by":"publisher","unstructured":"Longo MA et al (Dec. 2023) RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles. Nat Commun 14(1). https:\/\/doi.org\/10.1038\/s41467-023-40096-1","DOI":"10.1038\/s41467-023-40096-1"},{"key":"10331_CR25","doi-asserted-by":"publisher","unstructured":"Tien JCY et al (Oct. 2024) CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell Rep Med 5(10):101758. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101758","DOI":"10.1016\/j.xcrm.2024.101758"},{"key":"10331_CR26","doi-asserted-by":"publisher","unstructured":"Clarke NW et al (Aug. 2022) Abiraterone and Olaparib for metastatic castration-resistant prostate Cancer. NEJM Evid 1(9). https:\/\/doi.org\/10.1056\/evidoa2200043","DOI":"10.1056\/evidoa2200043"},{"key":"10331_CR27","doi-asserted-by":"publisher","unstructured":"Hussain M et al (2022) Tumor Genomic Testing for >\u20094,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib), Clinical Cancer Research, vol. 28, no. 8, pp. 1518\u20131530, Apr. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3940","DOI":"10.1158\/1078-0432.CCR-21-3940"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10331-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10331-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10331-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T08:39:06Z","timestamp":1745397546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10331-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["10331"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10331-8","relation":{},"ISSN":["1573-7276"],"issn-type":[{"type":"electronic","value":"1573-7276"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}